May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Evaluation of the Effect of D–Timolol on Rat Experimental Choroidal Neovascularization (CNV) in vivo and Endothelial Cells in vitro
Author Affiliations & Notes
  • Y. Zou
    Medical pharmacology & Toxicology, Texas A&M University System Health Science Center, College station, TX
  • X. Xu
    Medical pharmacology & Toxicology, Texas A&M University System Health Science Center, College station, TX
  • G.C. Y. Chiou
    Medical pharmacology & Toxicology, Texas A&M University System Health Science Center, College station, TX
  • Footnotes
    Commercial Relationships  Y. Zou, None; X. Xu, None; G.C.Y. Chiou, None.
  • Footnotes
    Support  Texas A&M System Health Science Center
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3024. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Zou, X. Xu, G.C. Y. Chiou; Evaluation of the Effect of D–Timolol on Rat Experimental Choroidal Neovascularization (CNV) in vivo and Endothelial Cells in vitro . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3024.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Impairment of choroidal perfusion was found in AMD patients. We postulated that vasoactive agents, which can reduce choroidal blood flow resistance, might prevent the development of CNV. D–Timolol is a hypotensive agent used in cardiovascular and glaucoma therapy. Its effect on laser–induced experimental CNV rat model and Human Umbilical Vein Endothelial Cells (HUVEC) were thus evaluated. Methods: (1) Male Brown Norway rats, weighing 150–200g were anesthetized to receive Nd:YAG laser to break the Bruch’s membrane. D–Timolol was given once daily through intraperitoneal injection after laser treatment at 5mg/Kg/d and 15mg/Kg/d for 4 weeks. Fluorescein angiography was performed on week two and week four with a digital fundus camera and standard fluorescein filter. (2) HUVEC from passage 2–7 were tested with proliferation assay and adhesion assay with D–timolol at concentrations of 1–100µg/ml. Results: D–timolol reduced the fluorescein leakage in laser–induced CNV model. The proportion of the prominent leaking lesions was reduced to 81.3% at dose of 15mg/kg/d compared with 96.8% in the control group. D–Timolol can also interfere the endothelial cells proliferation significantly. After incubation with D–Timolol for 48 hours, cells population was reduced to about 75% of the control group. Conclusions: D–Timolol was found to prevent CNV development in laser–induced model in vivo and inhibit vascular endothelial cells proliferation in vitro. It indicates that vasoactive drugs might be a new class of drugs that should be taken into consideration for AMD treatment although further investigation is needed.

Keywords: choroid: neovascularization • pharmacology • Bruch's membrane 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×